Papadimitriou Konstantinos, Kostopoulos Ioannis V, Tsopanidou Anastasia, Orologas-Stavrou Nikolaos, Kastritis Efstathios, Tsitsilonis Ourania, Dimopoulos Meletios A, Terpos Evangelos
Department of Biology, School of Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece.
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Cancers (Basel). 2020 Jul 22;12(8):2006. doi: 10.3390/cancers12082006.
Multiple myeloma (MM) remains incurable despite the abundance of novel drugs. As it has been previously shown, preclinical 2D models fail to predict disease progression due to their inability to simulate the microenvironment of the bone marrow. In this review, we focus on 3D models and present all currently available ex vivo MM models that fulfil certain criteria, such as development of complex 3D environments using patients' cells and ability to test different drugs in order to assess personalized MM treatment efficacy of various regimens and combinations. We selected models representing the top-notch ex vivo platforms and evaluated them in terms of cost, time-span, and feasibility of the method. Finally, we propose where such a model can be more informative in a patient's treatment timeline. Overall, advanced 3D preclinical models are very promising as they may eventually offer the opportunity to precisely select the optimal personalized treatment for each MM patient.
尽管有大量新型药物,但多发性骨髓瘤(MM)仍然无法治愈。如先前所示,临床前二维模型由于无法模拟骨髓微环境,无法预测疾病进展。在本综述中,我们聚焦于三维模型,并介绍所有目前可用的符合特定标准的体外MM模型,例如使用患者细胞构建复杂的三维环境,以及能够测试不同药物以评估各种方案和组合的个性化MM治疗效果。我们选择了代表顶尖体外平台的模型,并从成本、时间跨度和方法的可行性方面对其进行评估。最后,我们提出这种模型在患者治疗时间表中何处能提供更多信息。总体而言,先进的三维临床前模型非常有前景,因为它们最终可能为每个MM患者精确选择最佳个性化治疗方案提供机会。